Protagonist Therapeutics Inc (PTGX)
$144.85 +0.35% Close Oct 30, 2026 Live
Protagonist Therapeutics stock today
Protagonist Therapeutics closed at $144.85 on October 30, 2026, up 0.35% on the day. Over the past year it returned +86.1% with dividends reinvested, against +12.4% for the S&P 500. Its market value is $9.32 billion.
$75.00$100.00$125.00$150.00
NovJan 2026MarMayJulSep
| Period | PTGX | S&P 500 (SPY) |
|---|---|---|
| 1 month | +2.8% | -0.9% |
| 3 months | +4.5% | +2.1% |
| Year to date | +65.8% | +11.7% |
| 1 year | +86.1% | +12.4% |
| 3 years | +914.4% | +88.5% |
| 5 years | +364.9% | +76.0% |
Key statistics
- Market value
- $9.32B
- P/E (trailing)
- 140.6
- Forward P/E
- 61.9
- Price / sales
- 33.0
- 52-week range
- $75.95 to $158.62
- Next report
- Nov 5, 2026 (estimated)
About Protagonist Therapeutics
Develops monoclonal antibody therapies targeting gastrointestinal and inflammatory diseases.
Sector: Health Care
More on Protagonist Therapeutics
- Financials: revenue, earnings and segmentsRevenue -89% in the year to Dec 2025
- Valuation: P/E history and peersP/E 140.6
- Returns: what $1,000 became$1,000 ten years ago is $7,364 today
No forecast, no recommendation. This page describes Protagonist Therapeutics Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.